Tranylcypromine (Parnate) for sale
Tranylcypromine (Parnate) for sale; Tranylcypromine (sold under the trade name Parnate among others) is a monoamine oxidase inhibitor (MAOI); more specifically, tranylcypromine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively.
What is Tranylcypromine (Parnate)
Tranylcypromine (Parnate) for sale; Tranylcypromine (sold under the trade name Parnate among others) is a monoamine oxidase inhibitor (MAOI); more specifically, tranylcypromine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively. Tranylcypromine is a propylamine formed from the cyclization of amphetamine’s side chain; therefore, it is classified as a substituted amphetamine.
Tranylcypromine (Parnate) for sale; Tranylcypromine is used to treat major depressive disorder, including atypical depression, especially when there is an anxiety component, typically as a second-line treatment. It is also used in depression that is not responsive to reuptake inhibitor antidepressants, such as the SSRIs, TCAs, or bupropion
Adverse effects of Tranylcypromine (Parnate).
- Tachycardia (5-10%)
- Hypomania (7%)
- Paresthesia (5%)
- Weight loss (2%)
- Confusion (2%)
- Dry mouth (2%)
- Sexual function disorders (2%)
- Hypertension (1–2 hours after ingestion) (2%)
- Rash (2%)
- Urinary retention (2%)
Other (unknown incidence) adverse effects include:
- Increased/decreased appetite
- Blood dyscrasias
- Chest pain
- Leg cramps
- Sensation of cold
- Suicidal ideation
Of note, there has not been found to be a correlation between sex and age below 65 regarding incidence of adverse effects. Tranylcypromine is not associated with weight gain and has a low risk for hepatotoxicity compared to the hydrazine MAOIs. It is generally recommended that MAOIs be discontinued prior to anesthesia; however, this creates a risk of recurrent depression. In a retrospective observational cohort study, patients on tranylcypromine undergoing general anesthesia had a lower incidence of intraoperative hypotension, while there was no difference between patients not taking an MAOI regarding intraoperative incidence of bradycardia, tachycardia, or hypertension. The use of indirect sympathomimetic drugs or drugs affecting serotonin reuptake, such as meperidine or dextromethorphan poses a risk for hypertension and serotonin syndrome respectively; alternative agents are recommended. Other studies have come to similar conclusions. Pharmacokinetic interactions with anesthetics are unlikely, given that tranylcypromine is a high-affinity substrate for CYP2A6 and does not inhibit CYP enzymes at therapeutic concentrations.
Tranylcypromine (Parnate) for sale; Tranylcypromine abuse has been reported at doses ranging from 120–600 mg per day. It is thought that higher doses have more amphetamine-like effects and abuse is promoted by the fast onset and short half-life of tranylcypromine. Cases of suicidal ideation and suicidal behaviours have been reported during tranylcypromine therapy or early after treatment discontinuation. Symptoms of tranylcypromine overdose are generally more intense manifestations of its usual effects